Latham & Watkins advised Harmony Biosciences, while Paul Hastings LLP advised J.P. Morgan as the sole book-running manager in the offering. Harmony Biosciences Holdings, Inc. (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Dorsey & Whitney advised Rezolute, while Paul Hastings advised Jefferies and Cantor as joint book-running managers in the offering. Rezolute, Inc. (Nasdaq: RZLT) completed its underwritten...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell advised ProKidney, while Paul Hastings advised Jefferies, J.P. Morgan, and Guggenheim Securities, as joint book-running managers, in the transaction. ProKidney Corp. (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Monte Rosa Therapeutics, while Paul Hastings advised TD Cowen and Wedbush PacGrow, as joint book-running managers, in the offering. Monte Rosa Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Leerink Partners and Stifel as joint bookrunning managers in the offering. Evolus, Inc. (Nasdaq: EOLS) announced the pricing of its underwritten offering...
You must be a Standard 1 Year member to access this content.
Covington & Burling represented Humacyte, while Paul Hastings advised TD Cowen, Cantor and BTIG in the offering. Humacyte, Inc. executed an underwritten public offering of 13,400,000 shares...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Leerink Partners on the matter. PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Jefferies LLC as sole book running manager in connection with Esperion Therapeutics, Inc.’s offering. Esperion Therapeutics, Inc. announced the pricing of its...
You must be a Standard 1 Year member to access this content.
